Healthcare provider profile · identity verified

Leah Abbott, MD

Family Practice · GWINN, MI · NPI 1760987341

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	308	58
Levothyroxine Sodium	Levothyroxine Sodium	295	41
Amlodipine Besylate	Amlodipine Besylate	289	45
Omeprazole	Omeprazole	284	39
Gabapentin	Gabapentin	256	44
Atorvastatin Calcium	Atorvastatin Calcium	241	47
Lisinopril	Lisinopril	221	31
Furosemide	Furosemide	212	29
Losartan Potassium	Losartan Potassium	199	32
Metoprolol Tartrate	Metoprolol Tartrate	187	24
Quetiapine Fumarate	Quetiapine Fumarate	187	15
Sertraline Hcl	Sertraline Hcl	161	22
Metoprolol Succinate	Metoprolol Succinate	152	25
Trazodone Hcl	Trazodone Hcl	134	22
Tamsulosin Hcl	Tamsulosin Hcl	125	19
Citalopram Hbr	Citalopram Hydrobromide	123	12
Simvastatin	Simvastatin	98	13
Meloxicam	Meloxicam	97	14
Albuterol Sulfate Hfa	Albuterol Sulfate	91	30
Mirtazapine	Mirtazapine	88	14
Xarelto	Rivaroxaban	81	12
Duloxetine Hcl	Duloxetine Hcl	79	18
Risperidone	Risperidone	78	suppressed
Clopidogrel	Clopidogrel Bisulfate	77	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	77	13
Montelukast Sodium	Montelukast Sodium	74	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	71	14
Venlafaxine Hcl Er	Venlafaxine Hcl	71	suppressed
Metformin Hcl	Metformin Hcl	70	15
Potassium Chloride	Potassium Chloride	67	16
Pravastatin Sodium	Pravastatin Sodium	67	suppressed
Tramadol Hcl	Tramadol Hcl	66	18
Buspirone Hcl	Buspirone Hcl	65	13
Lorazepam	Lorazepam	64	13
Spironolactone	Spironolactone	64	suppressed
Eliquis	Apixaban	63	18
Finasteride	Finasteride	57	suppressed
Carbamazepine	Carbamazepine	56	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	55	12
Levetiracetam	Levetiracetam	55	suppressed
Famotidine	Famotidine	53	11
Lamotrigine	Lamotrigine	52	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	51	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	49	12
Fentanyl	Fentanyl	48	suppressed
Fluticasone Propionate	Fluticasone Propionate	48	14
Olanzapine	Olanzapine	47	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	46	14
Bumetanide	Bumetanide	43	suppressed
Ezetimibe	Ezetimibe	43	suppressed
Cephalexin	Cephalexin	42	25
Ibuprofen	Ibuprofen	40	16
Latanoprost	Latanoprost	39	suppressed
Allopurinol	Allopurinol	38	suppressed
Donepezil Hcl	Donepezil Hcl	38	suppressed
Carvedilol	Carvedilol	37	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	36	suppressed
Myrbetriq	Mirabegron	36	suppressed
Amiodarone Hcl	Amiodarone Hcl	35	suppressed
Clonazepam	Clonazepam	34	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	33	12
Methylphenidate Hcl	Methylphenidate Hcl	32	suppressed
Tizanidine Hcl	Tizanidine Hcl	32	suppressed
Nystatin	Nystatin	31	14
Jardiance	Empagliflozin	30	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	suppressed
Divalproex Sodium	Divalproex Sodium	29	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	28	suppressed
Morphine Sulfate	Morphine Sulfate	28	suppressed
Warfarin Sodium	Warfarin Sodium	28	suppressed
Prednisone	Prednisone	27	17
Propranolol Hcl	Propranolol Hcl	27	suppressed
Chlorthalidone	Chlorthalidone	26	suppressed
Oxycodone Hcl	Oxycodone Hcl	26	suppressed
Alprazolam	Alprazolam	25	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	12
Phenobarbital	Phenobarbital	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Unifine Safecontrol Pen Needle	Pen Needle,dual Safety,diabetc	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	18
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	22	suppressed
Glipizide	Glipizide	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	20	suppressed
Baclofen	Baclofen	19	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	18	suppressed
Lansoprazole	Lansoprazole	18	suppressed
Morphine Sulfate Er	Morphine Sulfate	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	18	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Naproxen	Naproxen	17	suppressed
Torsemide	Torsemide	17	suppressed
Vraylar	Cariprazine Hcl	17	suppressed
Ketoconazole	Ketoconazole	16	suppressed
Metformin Hcl Er	Metformin Hcl	16	suppressed
Aripiprazole	Aripiprazole	15	suppressed
Azithromycin	Azithromycin	15	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	15	suppressed
Raloxifene Hcl	Raloxifene Hcl	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Trimethoprim	Trimethoprim	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Haloperidol	Haloperidol	14	suppressed
Topiramate	Topiramate	14	suppressed
Alphagan P	Brimonidine Tartrate	13	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	11
Entresto	Sacubitril/Valsartan	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Lumigan	Bimatoprost	13	suppressed
Celecoxib	Celecoxib	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Galantamine Hbr	Galantamine Hbr	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Liothyronine Sodium	Liothyronine Sodium	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Etodolac	Etodolac	11	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error